ArticleOncology letters2026
Prognostic impact of low skeletal muscle mass in stage I-III colon cancer: A retrospective study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer (CC) is a common malignancy. Although the TNM staging system is widely employed for prognosis, its ability to predict individual patient outcomes is limited. In recent years, however, low skeletal muscle mass (SM) has emerged as a marked prognostic factor in patients with cancer. The present study aimed to investigate the prognostic value of low SM in patients with stage I-III CC. The present retrospective analysis included 230 patients with CC who underwent tumor resection at Lanzhou University Second Hospital (Lanzhou, China). The skeletal muscle index (SMI) was assessed using preoperative abdominal CT scans. Patients were stratified into low SM and non-sarcopenia groups based on their SMI. The primary outcome was overall survival (OS). The prognostic significance of low SM was evaluated using Kaplan-Meier survival curves, Cox regression modeling and time-dependent receiver operating Characteristic analysis. Furthermore, a combined TNM and low SM model was developed. Among the 230 patients, results showed that 24.34% exhibited low SM. Kaplan-Meier curves indicated that patients in the low SM group exhibited significantly lower OS rates compared with the normal SM group (P<0.001). Cox regression identified low SM as an independent adverse prognostic factor (hazard ratio: 1.70; 95% CI: 1.05-2.75). Incorporating low SM into the TNM model increased the Harrell's C-index from 0.570 to 0.604 (likelihood ratio P=0.027), with improved predictive performance at 1, 3 and 5-year time points. Overall, the present study concluded that low SM was an independent prognostic factor for OS in patients with stage I-III CC and a valuable supplement to existing prognostic tools, further contributing to personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.